No profile data available.
Xortx Therapeutics Inc. (XRTX) is a healthcare company in the metabolic process treatment drugs industry, based in Calgary, Canada.
It reported revenue of $0 for fiscal year 2024, and net income of -$3.31 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $0. Its market capitalization was $2.56 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.
Xortx Therapeutics reported $0 in revenue for fiscal year 2024. In Q2 2025 revenue was $0.
$2.56 million as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include Cartesian Therapeutics, Inc. (RNAC), Camp4 Therapeutics Corp (CAMP), Protalix BioTherapeutics, Inc. (PLX).